ArticleFrontiers in immunology2025
Panel of three cytokines predicts occurrence of aGVHD after allo-HSCT: a retrospective study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Many cytokines have been used as candidate biomarkers of acute graft-versus-host disease (aGVHD). Among these, the roles of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, IL-10, IL-17A, and IL-1β in aGVHD remain debatable, whereas IL-2, IL-12P70, IL-4, IL-5, and IFN-α are key elements in the pathological process of aGVHD. This study aimed to verify whether these 12 cytokines could serve as potential biomarkers of aGVHD in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: In this retrospective study, 155 patients were stratified into control (non-aGVHD) and experimental (aGVHD) groups based on the occurrence of aGVHD. The association between cytokine levels and aGVHD occurrence was evaluated. Results: The expression levels of IL-5, IL-8, and IL-10 were significantly elevated in patients with aGVHD compared to those in patients without aGVHD. The results of multivariate analysis revealed that IL-5, IL-8, and IL-10 were independent risk variables for aGVHD. These three cytokines formed a composite biomarker panel with a good predictive ability for aGVHD. The panel remained an independent predictor in multivariable analysis (HR = 3.34, 95% CI: 1.66 - 6.69, P < 0.001). The composite biomarker panel demonstrated robust discriminative performance upon internal validation with 1000 bootstrap resamples. Discussion: The composite biomarker panel comprising IL-5, IL-8, and IL-10 may serve as an important biomarker for predicting aGVHD occurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.